The study investigated r ezatapopt (PC14586), a first-in-class small molecule designed to selectively bind and reactivate the ...

Scientists at The Wistar Institute have solved a longstanding puzzle in ovarian cancer treatment: why anti-estrogen therapy often fails even when tumors express the hormone receptor that should make ...

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

A therapy that targets a mutation in a critical tumor suppressor gene exhibited “impressive” activity in a cohort of heavily ...

Research by Rutgers Cancer Institute of New Jersey investigators shows the targeting of a binding protein of mutant p53 known as Rac1 could lead to new therapeutic strategies for patients whose cancer ...

Discover how TP53 mutations in adult leukaemia impact treatment outcomes and potential strategies for improved patient care.

The gene p53 acts as a tumor suppressor and is often called the guardian of the genome. This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to ...

Schematic illustrating the effects of p53C and M237I in driving the conversion of p63C and p73C droplets into amyloid aggregates at physiologically relevant temperatures. Heparin prevents the ...

In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...